The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial.
Julia Katharina Neugebauer
No relevant relationships to disclose
Brigitte Kathrin Rack
Research Funding - Veridex
Bernadette Anna Sophia Jaeger
No relevant relationships to disclose
Ulrich Andergassen
No relevant relationships to disclose
Aurelia Pestka
No relevant relationships to disclose
Peter A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Amgen; Northwest Biotherapeutics
Thomas W. P. Friedl
No relevant relationships to disclose
Doraid Mouarrawy
No relevant relationships to disclose
Michael R. Clemens
No relevant relationships to disclose
Gabriele Ziemendorff
No relevant relationships to disclose
Georg Heinrich
No relevant relationships to disclose
Ekkehard von Abel
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Lilly; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - Lilly; Sanofi
Matthias W. Beckmann
No relevant relationships to disclose
Klaus Pantel
No relevant relationships to disclose
Wolfgang Janni
Consultant or Advisory Role - Veridex
Research Funding - Veridex
Expert Testimony - Veridex